Ratings BioSyent Inc.

Equities

RX

CA0906901081

Market Closed - Toronto S.E. Other stock markets 01:08:59 29/06/2024 am IST			5-day change	1st Jan Change
10 ^CAD	-3.57%		-4.76%	+8.46%

17/05	Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023.	CI
17/05	BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BIOSYENT INC.	+8.46%	84.69M	-	-
ELI LILLY AND COMPANY	+55.32%	815B		C+
NOVO NORDISK A/S	+44.05%	641B		B
JOHNSON & JOHNSON	-6.75%	352B		C+
MERCK & CO., INC.	+13.56%	314B		B-
ABBVIE INC.	+10.68%	303B		C+
ASTRAZENECA PLC	+16.57%	242B		B+
NOVARTIS AG	+13.31%	218B		B-
AMGEN INC.	+8.48%	168B		C+
PFIZER, INC.	-2.81%	159B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes